[General Information]
[Abstracts]
[How to Contact Us]
 

EFFICACY OF HYDRAZINE SULFATE IN THE TREATMENT OF CANCER

Joseph Gold
Syracuse Cancer Research Institute, Syracuse, N.Y.

April 2, 2013

This is the first official notice of the efficacy of hydrazine sulfate in the treatment of human cancer.

For years the Syracuse Cancer Research Institute has known of and publicized the efficacy and safety of hydrazine sulfate in the treatment of human cancer. Controlled clinical trials of this drug performed from 1976 through 1990 in accordance with internationally accepted standards (the Helsinki Declaration) demonstrated that for every million late-stage, unresponsive cancer patients treated with hydrazine sulfate, the drug developed by the SCRI, a half-million (50%) will respond with measurable symptomatic improvement, 400,000 (40%) will obtain tumor stabilization or regression (either no further tumor growth or tumor shrinkage), and some will go on to long term (>10 years) “complete response,” i.e., survival. These controlled clinical studies included ten years of Phase III randomized, placebo-controlled trials at Harbor-UCLA Cancer Center in Torrance, CA and 17 years of multicentric Phase II equivalent trials headquartered at the N. N. Petrov Research Institute of Oncology in St. Petersburg, Russia. These positive trials were all published in premier American peer-reviewed medical journals.

Only three controlled trials, all sponsored by the National Cancer Institute, have failed to show positive effects. However, all three trials were in violation of Principle 1 (the “generally accepted standards” rule) of the Helsinki Declaration by virtue of their use of incompatible agents (medications) with the test drug and therefore declared by this Declaration to have no scientific standing. Despite this, the NCI has consistently published the negative outcome of its sponsored trials, with the result that the use of this drug has become controversial.

No further controlled studies could be done. For this reason the SCRI felt it necessary to await further news of confirmation of drug effect before being justified in making a formal announcement to the public of drug efficacy.

Over the past 20 years the SCRI has acted as a central headquarters in receiving reports from thousands of doctors, veterinarians and individuals regarding their patients, loved ones and pets with cancer, treated with hydrazine sulfate alone. At this time we can disclose to the public that the results of all these single case reports seem to be identical to the combined controlled clinical studies of Harbor-UCLA and the N. N. Petrov Research Institute of Oncology quoted above: 50% measurable symptomatic improvement, 40% tumor stabilization or regression, 5%-10% long term “complete response,” i.e., survival. And these are in very advanced patients. Even better results have been reported in early or newly diagnosed patients.

As long time director of the Syracuse Cancer Research Institute I’ll point my finger—as did Babe Ruth almost a hundred years ago—to the “center field fence” and say that any cancer patient, even late-staged, treated with hydrazine sulfate without interfering medications or foods can expect a substantial chance of strongly beneficial results.

Joseph Gold, M.D.



This page is designed and hosted by Next Generation Computer Systems, and is the property of the Syracuse Cancer Research Institute. © 1996, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 04 June 1998 by
webteam@ngen.com.